Last reviewed · How we verify
[14C]D-0316 suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]D-0316 suspension ([14C]D-0316 suspension) — Betta Pharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]D-0316 suspension TARGET | [14C]D-0316 suspension | Betta Pharmaceuticals Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]D-0316 suspension CI watch — RSS
- [14C]D-0316 suspension CI watch — Atom
- [14C]D-0316 suspension CI watch — JSON
- [14C]D-0316 suspension alone — RSS
Cite this brief
Drug Landscape (2026). [14C]D-0316 suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-d-0316-suspension. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab